BARHEMSYS
Drug
Acacia Pharma Inc
Total Payments
$1.1M
Transactions
5,393
Doctors
3,603
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $52,501 | 767 | 725 |
| 2023 | $208,384 | 2,310 | 1,895 |
| 2022 | $213,238 | 795 | 524 |
| 2021 | $619,059 | 1,521 | 770 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $437,150 | 149 | 40.0% |
| Food and Beverage | $236,781 | 4,543 | 21.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $152,765 | 58 | 14.0% |
| Travel and Lodging | $120,265 | 594 | 11.0% |
| Honoraria | $116,750 | 36 | 10.7% |
| Unspecified | $29,348 | 1 | 2.7% |
| Education | $122.72 | 12 | 0.0% |
Payments by Type
General
$1.1M
5,392 transactions
Research
$29,348
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-Label Study of the Pharmacokinetics of Intravenous and Oral Amisulpride in Adults with Severe Renal Impairment and Healthy Control Subjects, Protocol DP 10026 | Acacia Pharma Inc | $29,348 | 0 |
Ad
Manufacturing Companies
- Acacia Pharma Inc $619,059
- EAGLE PHARMACEUTICALS, INC. $260,884
- ACACIA PHARMA INC $208,711
- Eagle Pharmaceuticals, Inc. $4,527
Product Information
- Type Drug
- Total Payments $1.1M
- Total Doctors 3,603
- Transactions 5,393
About BARHEMSYS
BARHEMSYS is a drug associated with $1.1M in payments to 3,603 healthcare providers, recorded across 5,393 transactions in the CMS Open Payments database. The primary manufacturer is Acacia Pharma Inc.
Payment data is available from 2021 to 2024. In 2024, $52,501 was paid across 767 transactions to 725 doctors.
The most common payment nature for BARHEMSYS is "Consulting Fee" ($437,150, 40.0% of total).
BARHEMSYS is associated with 1 research study, including "An Open-Label Study of the Pharmacokinetics of Intravenous and Oral Amisulpride in Adults with Severe Renal Impairment and Healthy Control Subjects, Protocol DP 10026" ($29,348).